Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice

References

• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325–1330.
   PubMed Web of Science ®Google Scholar
• Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflamma-tory and immunosuppressive mediators. Immunol Today 1997; 18: 428–432.
   Google Scholar
• Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704–1710.
   Google Scholar
• Suzuki Y, Yang Q, Conley FK, Abrams JS, Remington JS. Antibody against interleukin-6 reduces inflammation and num-bers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun 1994; 62: 2773–2778.
   Google Scholar
• Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zou JC, Abrams JS. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis fac-tor-a challenge in mice. J Immunol 1990; 145: 4185–4191.
   PubMed Web of Science ®Google Scholar
• Liu Z, Simpson RJ, Cheers C. Role of IL-6 in activation of T cells for acquired cellular resistance to Listeria monocyto-genes. J Immunol 1994; 152: 5375–5380.
   Google Scholar
• Dalrymple SA, Lucian LA, Slattery R, et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytoge-nes infection: correlation with inefficient neutrophilia. Infect Immun 1995; 63: 2262–2268.
   PubMed Web of Science ®Google Scholar
• Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64: 3231–3235.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show im-paired defence against pneumococcal pneumonia. J Infect Dis 1997; 176: 439–444.
   PubMed Web of Science ®Google Scholar
• Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kauf-mann SH. Lethal tuberculosis in interleukin-6-deficient mu-tant mice. Infect Immun 1997; 65: 4843–4849.
   Google Scholar
• Suzuki Y, Rani S, Liesenfeld 0, et al. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect Immun 1997; 65: 2339–2345.
   Google Scholar
• Moskowitz NH, Brown DR, Reiner SL. Efficient immunity against Leishmania major in the absence of interleukin-6. In-fect Immun 1997; 65: 2448–2450.
   Google Scholar
• Perry LL, Feilzer K, Caldwell HD. Neither interleukin-6 nor inducible nitric oxide synthase is required for clearance of Chlamydia trachomatis from the murine genital tract epithe-lffim. Infect Immun 1998; 66: 1265–1269.
   Google Scholar
• Castro M, Bjoraker JA, Rohrbach MS, Limper AH. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation 1996; 20: 107–122.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Klein TW, Friedman H. Involvement of man-nose receptor in cytokine interleukin-lbeta (IL-lbeta), IL-6, and granulocyte-macrophage colony-stimulating factor re-sponses, but not in chemokine macrophage inflammatory protein lbeta (MIP-lbeta), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect Immun 1997; 65: 1077–1082.
   Google Scholar
• Steinshamn S, Waage A. Tumor necrosis factor and inter-leukin-6 in Candida albicans infection in normal and granulo-cytopenic mice. Infect Immun 1992; 60: 4003–4008.
   PubMed Web of Science ®Google Scholar
• Romani L, Mencacci A, Cenci E, et al. Impaired neutrophil response and CD4T helper cell 1 development in inter-leukin 6-deficient mice infected with Candida albicans. J Exp Med 1996; 183: 1345–1355.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16: 51–55.
   PubMed Web of Science ®Google Scholar
• Leijh PCJ, Van den Barselaar MT, Van Furth R. Kinetics of phagocytosis and intracellular killing of Candida albicans by human granulocytes and monocytes. Infect Immun 1977; 17: 313–318.
   PubMed Web of Science ®Google Scholar
• Van't Wout JW, Linde I, Leijh PCJ, Van Furth R. Contribu-tion of granulocytes and monocytes to resistance against ex-perimental disseminated Candida albicans infections. Eur J Clin Microbiol Infect Dis 1988; 7: 736–741.
   Google Scholar
• Kullberg BJ, Netea MG, Curfs JHAJ, Keuter M, Meis JFGM, Van der Meer JWM. Recombinant murine granulo-cyte colony-stimulating factor protects against acute dissemi-nated Candida albicans infection in non-neutropenic mice. J Infect Dis 1998; 177: 175–181.
   Google Scholar
• Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-7 and tumor necrosis factor. J Immunol 1986; 137: 2980–2984.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Van't Wout JW, Hoogstraten C, Van Furth R. Recombinant interferon-7 enhances resistance to acute dis-seminated Candida albicans infection in mice. J Infect Dis 1993; 168: 436–443.
   PubMed Web of Science ®Google Scholar
• Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339–342.
   PubMed Web of Science ®Google Scholar
• Lehrer RI, Cline MJ. Interactions of Candida albicans with human leukocytes and serum. J Bacteriol 1969; 98: 996–1004.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Van't Wout JW, Van Furth R. Role of granulo-cytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319–3324.
   Google Scholar
• Kullberg BJ, Van't Wout JW, Van Furth R. No effect of recombinant human interleukin-1 on the numbers of periph-eral blood and peritoneal leukocytes during an acute inflam-mation. Inflammation 1991; 15: 457–470.
   Google Scholar
• Van't Wout JW, Linde I, Leijh PCJ, Van Furth R. Effect of irradiation, cyclophosphamide, and etoposide (VP-16) on number of peripheral blood and peritoneal leukocytes in mice under normal conditions and during acute inflammatory reac-tion. Inflammation 1989; 13: 1–14.
   PubMed Web of Science ®Google Scholar
• Lonnemann G, Endres S, Van der Meer JWM, Cannon JG, Koch KM, Dinarello CA. Differences in the synthesis and kinetics of release of interleukin-la, interleukin-113 and tumor necrosis factor from human mononuclear cells. Eur J Im-munol 1989; 19: 1531–1536.
   Google Scholar
• Netea MG, Demacker PNM, Kullberg BJ, et al. Low-density-lipoprotein receptor deficient mice are protected against lethal endotoxinemia and severe Gram-negative infections. J Clin Invest 1996; 97: 1366–1372.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095–2147.
   PubMed Web of Science ®Google Scholar
• Romani L. The T cell response against fungal infections. Curr Opin Immunol 1997; 9: 484–490.
   PubMed Web of Science ®Google Scholar
• Puccetti P, Mencacci A, Cenci E, et al. Cure of murine can-didiasis by recombinant soluble interleukin-4 receptor. J In-fect Dis 1994; 169: 1325–1331.
   Web of Science ®Google Scholar
• Romani L, Puccetti P, Mencacci A, et al. Neutralization of IL-10 up-regulates nitric oxide production and protects sus-ceptible mice from challenge with Candida albicans. J Im-munol 1994; 152: 3514–3521.
   PubMed Web of Science ®Google Scholar
• Cassone A, Palma C, Djeu JY, Aiuti F, Quinti I. Anticandi-dal activity and interleukin-l-beta and interleukin-6 produc-tion by polymorphonuclear leukocytes are preserved in subjects with AIDS. J Clin Microbiol 1993; 31: 1354–1357.
   Google Scholar
• Ueta E, Umazume M, Yamamoto T, Osaki T. Enhancement of polymorphonuclear leukocyte (PMN) function by 0K-432. Int J Immunopharmacol 1994; 16: 7–17.
   PubMed Web of Science ®Google Scholar
• Netea MG, Van Tits LHJ, Curfs JAHJ, et al. The increased susceptibility of TNFaLTa double knock-out mice to sys-temic candidiasis is due to defective recruitment and phago- cytosis by neutrophils. In: 38th Interscience Conference on An-timicrobial Agents and Chemotherapy, San Diego, CA, 1998. Washington: Am Soc Microbiol, Abstract G44.
   Google Scholar
• Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 8093–8098.
   PubMed Web of Science ®Google Scholar
• Van der Meer JWM. Options for the treatment of serious infections with interleukin-1. Biotherapy 1989; 1: 313–317.
   PubMedGoogle Scholar